Short and medium term effects of exenatide treatment in a cohort of type 2 diabetic patients: Results of a multicentric study within the diabetologists network of UCL;Effets à court et moyen terme d'un traitement par exénatide dans une cohorte de patients diabétiques de type 2: Résultats d'une étude multicentrique au sein du Réseau des diabétologues de l'UCL

Louvain Medical

Volumn 129, Issue 2, 2010, Pages 49-53

  Buysschaert, M ^a   Claessens, A ^b   Damoiseaux, P ^c   Derdelinckx, L ^d   Dramais, A S ^e   Duvivier, E ^f   Godart, V ^g   Hermans, M P ^a   Ippersiel, V ^h   Leonet J ⁱ   Oriot, Ph ^j   Paris, I ^f   Ponchon, M ^k   Preumont, V ^a   Proces S ^l   Scarniere D ^l   Selvais, Ph ^m   Thissen, J P ^a   Vandeleene, B ^a   Warnotte, C ⁿ  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b Cliniques du Sud Luxembourg   (Belgium)

^c Centre Hospitalier de Dinant   (Belgium)

^d Clinique St Luc Bouge   (Belgium)

^e Centre Hospitalier Regional de Namur   (Belgium)

^f Centre Hospitalier Notre Dame et Reine Fabiola   (Belgium)

^g Cliniques de l'Europe   (Belgium)

^h UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

ⁱ Centre Hospitalier Peltzer La Tourelle   (Belgium)

^j Centre Hospitalier   (Belgium)

^k Saint Jean Clinic of Brussels   (Belgium)

^l Cliniques St Joseph Ste Thérèse et Imtr ^*  (Belgium)

^m Centre Hospitalier Homu Framerles   (Belgium)

ⁿ Clinique Notre Dame de Grace   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; DRUG EFFICACY; DRUG SCREENING; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT DURATION; WEIGHT;

EID: 77949381527     PISSN: 00246956     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-853.
2. The ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358:2560-2572.
3. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC et al.: Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009; 52:2288-2298.
4. The Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358:2545-2559.
5. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al., for the VADT Investigators: Glucose control and vascular complications in Veterans with type 2 diabetes. New Engl J Med. 2009; 360:129-139.
6. Buysschaert M, Medina JL : L'optimisation glycémique suffit-elle à prévenir une macroangiopathie chez le diabétique de type 2 ? Louvain Med. 2009; 3:S27-S31.
7. American Diabetes Association : Standards of medical care in diabetes-2009. Diabetes Care. 2009; 32(suppl.1):S6-S13.
8. Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358:580-591.
9. Buysschaert M. Diabétologie clinique. De Boeck Université, 3e Edition , Paris, Bruxelles, 2006.
10. Preumont V : Les incrétines [analogues du GLP-1 et inhibiteurs de la DPP-4] dans le traitement du diabète de type 2. Louvain Med. 2009 ; 3:S37-S45.
11. Buysschaert M : Le concept des incrétines et son application thérapeutique (agonistes du récepteur du GLP-1 ; gliptines) dans le diabète de type 2. Louvain Med. 2009; 9:281-288.
12. Lienart D, Preumont V, Alexopoulou O, Donckier J, Colson A, Hermans MP, Buysschaert M: Metabolic (glycaemic, lipidic) and blood pressure control in 101 type 2 diabetic patients on first admission to diabetes centres. Acta Clinica Belgica. 2006; 61(3):127-133.
13. De Fronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (Exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005:28:1092-1100.
14. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in surfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004; 27:2628-2635.
15. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD: Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care. 2005; 28:1083-1091.
16. Riddle MC, Henry RR, Poon TH, Zhang B, Mac SM, Holcombe JH. Maggs: Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulfonylureas with or without metformin. Diabetes, Metabolism Research and Reviews. 2006; 22:483-491.
17. Preumont V, Hermans M, Brichard S, Buysschaert M: 6-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity: Diabetes & Metab. 2010; Accepted.
18. Holman RR, Famner AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF et al , for the T-4 Study Group : Three-year efficacy of complex insulin regimens in type 2 diabetes. New Engl J Med. 2009; 361:1736-47.
19. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Inter Med. 2005; 143:559-569.
20. Nauck MA, Duran S, Kim D, Johns D, Northrop J, Festa A, et al.: A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who where suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007; 50:259-267.
21. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH et al.: Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res. 2008; 24(1):275-286.
22. Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian RM et al.: One-year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients. A randomized control trial. Diabetes Care. 2009; 32:762-768.
23. http://www.fda.gov/cder/drug/infopage/exenatide/default.htm
24. De Block C, Paquot N, Daoudi N, Ballaux D, Van Gaal LF, Scheen AJ : Amélioration du contro̊le glycémique et perte de poids sous exénatide chez des patients diabétiques de type 2 : résultats d'une étude rétrospective observationnelle multicentrique belge. Rev Med Liège. 2009; 64(10):488-495.
25. Buysschaert M, for the UCL Exenatide Study Group. One year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. In preparation.